论文部分内容阅读
目的:深入研究奥沙利铂与吉西他滨联合治疗胰腺癌的临床疗效。方法:选取于2013年6月-2015年6月期间在我院肿瘤科接受治疗的74例胰腺癌患者,将患者随机分为对照组35例患者、治疗组39例患者进行对照研究,观察并比较吉西他滨与奥沙利铂联合吉西他滨治疗的效果。结果:治疗组患者的治疗总有效率与不良反应发生率分别为94.9%和10.3%,与对照组患者的74.3%和28.6%比较,差异显著,治疗有统计学意义(P<0.05)。结论:奥沙利铂与吉西他滨联合治疗胰腺癌能够取得显著的效果,大大降低了不良反应发生情况,对提高患者的生存时间具有十分重要的作用和意义。
Objective: To study the clinical efficacy of oxaliplatin combined with gemcitabine in the treatment of pancreatic cancer. Methods: Seventy-four patients with pancreatic cancer undergoing oncology in our hospital from June 2013 to June 2015 were randomly divided into control group (35 patients) and control group (39 patients) To compare the efficacy of gemcitabine and oxaliplatin in combination with gemcitabine. Results: The total effective rate and adverse reaction rate in the treatment group were 94.9% and 10.3%, respectively, which were significantly different from those in the control group (74.3% and 28.6%). The treatment was statistically significant (P <0.05). Conclusion: Combined treatment of oxaliplatin and gemcitabine can achieve significant effect on pancreatic cancer, greatly reduce the incidence of adverse reactions, and play an important role in improving the survival time of patients.